Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Receivables - Net: 2019-2025

Historic Receivables - Net for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $43.6 million.

  • Pharming Group N.V's Receivables - Net fell 9.53% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year decrease of 9.53%. This contributed to the annual value of $54.8 million for FY2024, which is 18.77% up from last year.
  • Pharming Group N.V's Receivables - Net amounted to $43.6 million in Q3 2025, which was down 18.23% from $53.3 million recorded in Q2 2025.
  • Pharming Group N.V's Receivables - Net's 5-year high stood at $54.8 million during Q4 2024, with a 5-year trough of -$5.5 million in Q2 2023.
  • For the 3-year period, Pharming Group N.V's Receivables - Net averaged around $41.0 million, with its median value being $46.2 million (2023).
  • Its Receivables - Net has fluctuated over the past 5 years, first soared by 1,061,872.31% in 2022, then tumbled by 91.33% in 2023.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Receivables - Net stood at $30.0 million in 2021, then declined by 7.88% to $27.6 million in 2022, then surged by 67.12% to $46.2 million in 2023, then grew by 18.77% to $54.8 million in 2024, then decreased by 9.53% to $43.6 million in 2025.
  • Its Receivables - Net was $43.6 million in Q3 2025, compared to $53.3 million in Q2 2025 and $47.5 million in Q1 2025.